A phase 2, open-label, multicenter study of the safety of ritonavir-boosted GS-9137 [elvitegravir] (GS-9137/r) [elvitegravir/ritonavir] administered in combination with other antiretroviral agents for the treatment of HIV-1 infected subjects

Trial Profile

A phase 2, open-label, multicenter study of the safety of ritonavir-boosted GS-9137 [elvitegravir] (GS-9137/r) [elvitegravir/ritonavir] administered in combination with other antiretroviral agents for the treatment of HIV-1 infected subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Elvitegravir (Primary) ; Antiretrovirals; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 Jan 2015 According to ClinicalTrial.gov record, planned primary completion date changed from 1 Jan 2015 to 1 Apr 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top